Record exit for High-TechGründerfonds
The German biotech company MYR is going to the USA for 1.15 billion euros. High-Tech Gründerfonds, which had already joined as an early-stage investor, is particularly pleased.
It is a milestone for two companies at once and it is hard to say who is happier these days. The founders of German biotech start-up Myr Pharmaceuticals are likely to be delighted with a billion-euro exit to US pharmaceutical company Gilead and thus full cash. At High-Tech Gründerfonds (HTGF), meanwhile, they are not only celebrating an exit and a lot of money, but also the largest sale since the state-private early-stage investor was founded. Many millions of euros are likely to flow back to HTGF.
The US company Gilead paid EUR 1.15 billion for the Bad Homburg-based company, which recently made headlines with its drug "Hepcludex", in a positive sense. The drug is intended to help against hepatitis D infections and has been conditionally approved by the European Medicines Agency since this year. MYR expects American approval in 2021.
Newsletter
Startups, stories and stats from the German startup ecosystem straight to your inbox. Subscribe with 2 clicks. Noice.
LinkedIn ConnectFYI: English edition available
Hello my friend, have you been stranded on the German edition of Startbase? At least your browser tells us, that you do not speak German - so maybe you would like to switch to the English edition instead?
FYI: Deutsche Edition verfügbar
Hallo mein Freund, du befindest dich auf der Englischen Edition der Startbase und laut deinem Browser sprichst du eigentlich auch Deutsch. Magst du die Sprache wechseln?
